Cardiovascular disease to which hypertension (HTN) is a major contributor, has been named as the largest epidemic known to humankind. Hypertension remains a growing global concern, over the past three decades; HTN has increased from the fourth leading risk factor for global disease burden in 1990 for both females and males, to the first in females and the second in males in 2016. In 2008, a white paper was published by a group of researchers in HTN with a call for action to improve the control rates. Despite some significant scientific and economic advancements, five challenges associated with the management of HTN remain to date: inadequate primary prevention, limited awareness of risk, lack of simplicity in the treatments, therapeutic inertia, and insufficient patient empowerment.
High blood pressure is a clearly established, modifiable risk factor for early disability and death. Although most of the adverse cardiovascular outcomes occur in adulthood, it has become clear that high blood pressure is a problem across the course of life that may become evident in early life. Since the 1970s, the prevalence of hypertension in children has increased ~4-fold. This data is highly concerning as hypertension in childhood is typically associated with intermediate markers of target organ damage (e.g., left ventricular hypertrophy or thickening of the carotid vessel wall). As such, further research focusing on therapeutic interventions in early life and assessing the origins of this epidemic is a key issue. The current interest in the field of hypertension in youth, could lead to improvements in the quality and efficacy of care provided to patients and lead to secondary prevention of adverse cardiovascular events in later life.
This research topic aims to address key issues on the front line of the field of pediatric hypertension. This collection will highlight emerging research in the identification, evaluation, and management of children and adolescents with high blood pressure. We would like to invite the submission of original research, review, and perspective articles from leading researchers and early career researchers that address such issues within the field of pediatric and adolescent HTN.
Potential areas of research within this collection may include, but are not limited to:
1) Pediatric hypertension and cardiovascular risk in later life.
2) Management of primary hypertension in children and adolescents.
3) Management of secondary hypertension in children and adolescents.
4) Risk factors in the development of pediatric hypertension.
5) Blood pressure values and target organ damage.
6) Clinical trials for antihypertensive drugs in pediatric hypertension.
7) Management of hypertension in children with chronic kidney disease.
8) Primary hypertension as an immuno-metabolic disease.
9) Hypertension and Cardiometabolic Syndrome.
10) Reference values for blood pressure in children and adolescents.
Cardiovascular disease to which hypertension (HTN) is a major contributor, has been named as the largest epidemic known to humankind. Hypertension remains a growing global concern, over the past three decades; HTN has increased from the fourth leading risk factor for global disease burden in 1990 for both females and males, to the first in females and the second in males in 2016. In 2008, a white paper was published by a group of researchers in HTN with a call for action to improve the control rates. Despite some significant scientific and economic advancements, five challenges associated with the management of HTN remain to date: inadequate primary prevention, limited awareness of risk, lack of simplicity in the treatments, therapeutic inertia, and insufficient patient empowerment.
High blood pressure is a clearly established, modifiable risk factor for early disability and death. Although most of the adverse cardiovascular outcomes occur in adulthood, it has become clear that high blood pressure is a problem across the course of life that may become evident in early life. Since the 1970s, the prevalence of hypertension in children has increased ~4-fold. This data is highly concerning as hypertension in childhood is typically associated with intermediate markers of target organ damage (e.g., left ventricular hypertrophy or thickening of the carotid vessel wall). As such, further research focusing on therapeutic interventions in early life and assessing the origins of this epidemic is a key issue. The current interest in the field of hypertension in youth, could lead to improvements in the quality and efficacy of care provided to patients and lead to secondary prevention of adverse cardiovascular events in later life.
This research topic aims to address key issues on the front line of the field of pediatric hypertension. This collection will highlight emerging research in the identification, evaluation, and management of children and adolescents with high blood pressure. We would like to invite the submission of original research, review, and perspective articles from leading researchers and early career researchers that address such issues within the field of pediatric and adolescent HTN.
Potential areas of research within this collection may include, but are not limited to:
1) Pediatric hypertension and cardiovascular risk in later life.
2) Management of primary hypertension in children and adolescents.
3) Management of secondary hypertension in children and adolescents.
4) Risk factors in the development of pediatric hypertension.
5) Blood pressure values and target organ damage.
6) Clinical trials for antihypertensive drugs in pediatric hypertension.
7) Management of hypertension in children with chronic kidney disease.
8) Primary hypertension as an immuno-metabolic disease.
9) Hypertension and Cardiometabolic Syndrome.
10) Reference values for blood pressure in children and adolescents.
